Pfizer Ends Obesity Pill Development Over Liver Risks

Need2Know Headlines

Pfizer announcing this morning, they will stop development of their experimental obesity and type two diabetes drug Ron due to the risk of liver damage. Patients who took the pill during clinical trials showed elevated liver enzymes. Pfizer said no patients experienced liver problems or side effects. Instead, the drug maker is focusing its efforts on another oral treatment for obesity, which is currently in phase two clinical trials. According to data released by Pfizer, their drug had similar weight loss results to Novo Nordisk.